Breast cancer resistance to CDK4/6 inhibitors arises in many ways

Breast cancer resistance to CDK4/6 inhibitors arises in many ways

"We set out to identify how ER-positive breast cancer cells become resistant to CDK4/6 inhibitors, such as palbociclib, in order to identify potential combinations of anticancer agents that could delay the onset of resistance or overcome resistance

(Visited 1 times, 1 visits today)
3
Like
Save

Comments

Comments are disabled for this post.